Last reviewed · How we verify
Topical Prednisolone Acetate 1%
Prednisolone acetate is a topical corticosteroid that suppresses local inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Prednisolone acetate is a topical corticosteroid that suppresses local inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye, Allergic conjunctivitis.
At a glance
| Generic name | Topical Prednisolone Acetate 1% |
|---|---|
| Also known as | Topical Pred Forte 1% |
| Sponsor | New England Retina Associates |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone acetate reduces inflammation by inhibiting the release of inflammatory mediators, decreasing immune cell infiltration, and suppressing cytokine production at the ocular surface and anterior segment. The acetate ester formulation enhances corneal penetration compared to other prednisolone salts, allowing effective delivery of the active corticosteroid to intraocular tissues.
Approved indications
- Inflammation and pain following ocular surgery
- Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye
- Allergic conjunctivitis
- Anterior uveitis
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Secondary ocular infection
- Ocular irritation or discomfort
- Blurred vision
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (PHASE3)
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Prednisolone Acetate 1% CI brief — competitive landscape report
- Topical Prednisolone Acetate 1% updates RSS · CI watch RSS
- New England Retina Associates portfolio CI